StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Investment analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Down 0.6 %

Shares of BCLI stock opened at $1.58 on Tuesday. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89. The firm’s 50 day moving average is $1.83 and its 200-day moving average is $2.18. The firm has a market capitalization of $9.01 million, a price-to-earnings ratio of -0.33 and a beta of 0.74.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.